research 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
Baricitinib stops hair loss and promotes regrowth in alopecia areata.
Search
for
Sort by
Research
810-840 / 1000+ resultsresearch β-catenin-mediated hair growth induction effect of 3,4,5-tri-O-caffeoylquinic acid
3,4,5-tri-O-caffeoylquinic acid promotes hair growth by activating the β-catenin pathway.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research 873 The effect of Cilostazol on hair growth: A novel therapeutic option for the treatment of hair loss
Cilostazol may help hair grow and could be a new treatment for hair loss.
research Androstanediolglucuronide: A parameter for peripheral androgen activity before and during therapy with cyproterone acetate
3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.
research Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application
Improved finasteride formula allows slow, sustained release and better absorption for patients.
research Patient and Clinician‐Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD‐Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO‐SCALP Study
The cream effectively treats scalp psoriasis, improving symptoms and quality of life, with high patient satisfaction.
research Serum Level of Programmed Death Ligand1 in Alopecia Areata Patients in Relation to Disease Severity
Higher levels of PD-L1 are linked to more severe hair loss in people with Alopecia Areata.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Isolation of dioctyl phthalate with high depigmenting effect from Chinese herb Nigella glandulifera Freyn
research Chemistry, Pharmacology and Therapeutic Potential of Decursin: A Promising Natural Lead for New Drug Discovery and Development
Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
research Follicular-targeted delivery of spironolactone provided by polymeric nanoparticles
Nanoparticles can effectively deliver spironolactone to hair follicles for treating alopecia and acne.
research A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice
The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.
research CLINICAL EVALUATION OF HAIRBAC TABLET AND OIL IN THE MANAGEMENT OF DIFFUSE HAIR LOSS: AN OPEN CLINICAL STUDY
Hairbac tablet and oil significantly improve hair texture, density, and reduce hair loss without side effects.
research Targeting telomeric RNA quadruplexes with natural metabolites to prevent cancer
research Alopecia areata after dupilumab for atopic dermatitis
Dupilumab for eczema may cause hair loss.
research Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta‐Analysis
Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
research Phospholipid–polymer hybrid nanoparticle-mediated transfollicular delivery of quercetin: prospective implement for the treatment of androgenic alopecia
Quercetin-loaded nanoparticles can penetrate skin, minimize hair loss, and promote hair regrowth, showing slightly better results than a marketed product.
research A single topical application of calcipotriol (50μg/g) ointment has no acute effect on systemic calcium homeostasis in patients with chronic plaque psoriasis
Putting calcipotriol ointment on the skin once doesn't change calcium levels in the body right away.
research 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
Upadacitinib effectively treats pyoderma gangrenosum.
research The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
research Development and characterization of polydeoxyribonucleotide (PDRN) loaded chitosan polyplex: In vitro and in vivo evaluation of wound healing activity
The chitosan/PDRN polyplex improved wound healing in diabetic rats.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection
Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
research The physiological and pharmacological roles of prostaglandins in hair growth
Targeting the PGD2-DP2 pathway may help treat hair loss.
research Platelet‐rich plasma as a new and successful treatment for lichen planopilaris: A controlled blinded randomized clinical trial
Platelet-rich plasma (PRP) is an effective treatment for lichen planopilaris.
research 17α-Acetoxy-6-bromo-16β-methylpregna-4,6-diene-3,20-dione
A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
research 91. Association of Pilonidal Disease with Polycystic Ovarian Syndrome in Adolescent Females
Girls with Pilonidal Disease are more likely to have Polycystic Ovarian Syndrome, and treating PCOS may reduce the need for PD intervention.
research A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.